1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Scott T. DeGhetto's term as Executive Vice President and Chief Financial Officer ended April 1, 2026. On April 6, the company signed a one-year consulting agreement with him through his company, Emberstone, LLC, covering debt and equity financing, corporate dispositions and other market-related projects, and the filing shows Paul K. Ito signing as Chief Financial Officer. The agreement adds monthly fees and a special projects fee on top of a previously reported $800,000 consulting payment, which shareholders may track as a cost.
CFO term ended April 1, 2026 for Scott T. DeGhetto
Consulting agreement dated April 6, 2026, running to April 5, 2027
Monthly fee of $200,000 plus applicable taxes, and a $1,350,000 special projects fee at the end of the term
Separate $800,000 for consulting through March 1, 2027, previously reported from November 2024 compensation package
AppFolio entered a Second Amended and Restated Employment Agreement with CEO Shane Trigg on April 9, 2026, replacing his March 1, 2023 agreement. The deal sets a base salary of at least $570,000, a 100% of salary target bonus, and annual equity awards for fiscal 2026 through 2030, with enhanced severance terms including a 24-month salary continuation if terminated in connection with a corporate transaction.
Base salary of at least $570,000 and bonus target of 100% of base salary
Fiscal 2026 one-time awards: $5,000,000 RSU grant value and $4,479,000 PSU grant value at target
Fiscal 2027 through 2030: annual RSU grant value of $5,000,000 plus a formula-based PSU award
Corporate transaction termination: 24 months of salary continuation and 200% of annual bonus
Caterpillar's board appointed Kyle Epley, who joined the company in 1996 and has led Global Finance Services since 2019, as chief financial officer effective May 1, 2026, succeeding Andrew Bonfield. Bonfield remains CFO until May 1, 2026, then serves in an advisory role and retires October 1, 2026. The filing also sets Epley's annual salary at $930,500 and a long-term incentive grant with a grant-date fair value of $1.8 million.
Kyle Epley, 53, senior vice president of Global Finance Services, appointed CFO by the board on April 7, 2026, effective May 1, 2026
Andrew Bonfield, CFO, retires October 1, 2026; he serves in an advisory role through that date
Epley's annual salary rises to $930,500 effective May 1, 2026; target annual incentive set at 115% of base salary
Long-term incentive grant with a grant-date fair value of $1.8 million: half performance-based RSUs, one-quarter stock options, one-quarter time-based RSUs
Dynamix Corporation and The Ether Machine, Inc. mutually terminated their Business Combination Agreement dated July 21, 2025, along with the related Sponsor Support Agreement, under a Termination Agreement dated April 8, 2026. Under that agreement, the Payor must pay Dynamix $50 million within 15 days, and the parties exchanged mutual releases. Dynamix still has until November 22, 2026 to complete an initial business combination, or it must redeem its public shares.
Termination Agreement dated April 8, 2026 ends the Business Combination Agreement dated July 21, 2025, and the Sponsor Support Agreement dated July 21, 2025.
The Payor must pay Dynamix $50 million within 15 days of April 8, 2026.
Mutual releases and a covenant not to sue were included; Dynamix has until November 22, 2026 to complete an initial business combination or must redeem public shares.
Vir Biotechnology said its Executive Vice President and Chief Medical Officer, Mark Eisner, informed the company on April 7, 2026 that he will step down effective April 24, 2026. The company has started searching for a successor, and the filing does not name an interim replacement.
Mark Eisner, EVP and Chief Medical Officer, will step down effective April 24, 2026.
He informed the company of his decision on April 7, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.